Niko Andre

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial

David Cunningham, István Láng, Eugenio Marcuello et al. · The Lancet Oncology · 2013 · 642 citations

Elderly Patients, Gastrointestinal Oncology, Medicine +10

Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma

Ullrich Graeven, Niko Andre, E. Achilles et al. · Journal of Cancer Research and Clinical Oncology · 1999 · 102 citations · Full text

Angiogenesis, Soft-tissue Sarcoma, Pathology +5

Discs large (Dlg1) complexes in lymphocyte activation

Ramnik J. Xavier, Shahrooz Rabizadeh, Kazuhiro Ishiguro et al. · The Journal of Cell Biology · 2004 · 99 citations · Full text

Lymphocyte Activation, Adaptive Immune System, T-regulatory Cell +17

Expression Patterns of Placenta Growth Factor in Human Melanocytic Cell Lines

Ullrich Graeven, Sonja Karpinski, Niko Andre et al. · Journal of Investigative Dermatology · 2000 · 31 citations · Full text

Placenta Growth Factor, Embryology, Developmental Biology +9

Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX).

David Cunningham, István Láng, Vito Lorusso et al. · Journal of Clinical Oncology · 2013 · 31 citations

Elderly Patients, Cancer Management, Clinical Endpoint +17